Crescita Therapeutics Inc logo

CTX - Crescita Therapeutics Inc Share Price

C$0.51 -0.0  -3.8%

Last Trade - 10/07/20

Micro Cap
Market Cap £6.14m
Enterprise Value £1.56m
Revenue £12.8m
Position in Universe 1576th / 2667
Unlock CTX Revenue
Relative Strength (%)
1m -23.0%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -58.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.83 0.23 3.50 12.0 16.6 22.3 +93.2%
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Crescita Therapeutics Inc revenues decreased 10% to C$3.8M. Net loss totaled C$494K vs. income of C$42K. Revenues reflect Product sales segment decrease of 35% to C$1.5M, Out-licensing Revenue segment decrease of 19% to C$1.5M, Canada segment decrease of 13% to C$2.9M. Net loss reflects Amort Intangibles excl Goodwill in SGA increase of 24% to C$301K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


CTX Revenue Unlock CTX Revenue

Net Income

CTX Net Income Unlock CTX Revenue

Normalised EPS

CTX Normalised EPS Unlock CTX Revenue

PE Ratio Range

CTX PE Ratio Range Unlock CTX Revenue

Dividend Yield Range

CTX Dividend Yield Range Unlock CTX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CTX EPS Forecasts Unlock CTX Revenue
Profile Summary

Crescita Therapeutics Inc. is a drug development company. The Company owns products for treating medical conditions in dermatology and pain. It owns various drug delivery platforms, which include Durapeel and Foam technology to support the development of patented formulations that can deliver actives into or through the skin. It operates two business units: the Topical Products and Technology (TPT) Group and the Immunology Group. The TPT Group product, Pliaglis and other products are focused on dermatology and pain. Its product Flexicaine is in Phase II clinical stage and has therapeutic area in Tick-borne disease. Its product Ibuprofen Foam is in pre-clinical stage and has therapeutic area in Acute Pain. Its product Terbinafine is in pre-clinical stage and has therapeutic area in Onychomycosis. Its product Mical 1 is in pre-clinical stage and has therapeutic area in Psoriasis. Its product Mical 2 is in pre-clinical stage and has therapeutic area in Dermatological skin treatment.

Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated March 1, 2016
Public Since March 7, 2016
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Pharmaceuticals
Exchange Toronto Stock Exchange
Shares in Issue 20,648,448
Free Float (0.0%)
Eligible for
CTX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for CTX
Upcoming Events for CTX
Frequently Asked Questions for Crescita Therapeutics Inc
What is the Crescita Therapeutics Inc share price?

As of 10/07/20, shares in Crescita Therapeutics Inc are trading at C$0.51, giving the company a market capitalisation of £6.14m. This share price information is delayed by 15 minutes.

How has the Crescita Therapeutics Inc share price performed this year?

Shares in Crescita Therapeutics Inc are currently trading at C$0.51 and the price has moved by -53.64% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Crescita Therapeutics Inc price has moved by -50.9% over the past year.

What are the analyst and broker recommendations for Crescita Therapeutics Inc?

There are no analysts currently covering Crescita Therapeutics Inc.

When will Crescita Therapeutics Inc next release its financial results?

Crescita Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Crescita Therapeutics Inc dividend yield?

Crescita Therapeutics Inc does not currently pay a dividend.

Does Crescita Therapeutics Inc pay a dividend?

Crescita Therapeutics Inc does not currently pay a dividend.

When does Crescita Therapeutics Inc next pay dividends?

Crescita Therapeutics Inc does not currently pay a dividend.

How do I buy Crescita Therapeutics Inc shares?

To buy shares in Crescita Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Crescita Therapeutics Inc?

Shares in Crescita Therapeutics Inc are currently trading at C$0.51, giving the company a market capitalisation of £6.14m.

Where are Crescita Therapeutics Inc shares listed? Where are Crescita Therapeutics Inc shares listed?

Here are the trading details for Crescita Therapeutics Inc:

Country of listing: Canada
Exchange: TOR
Ticker Symbol: CTX
What kind of share is Crescita Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Crescita Therapeutics Inc is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Crescita Therapeutics Inc share price forecast 2020?

We were not able to load any forecast data for Crescita Therapeutics Inc.

How can I tell whether the Crescita Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Crescita Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -37.06%. At the current price of C$0.51, shares in Crescita Therapeutics Inc are trading at -35.93% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Crescita Therapeutics Inc PE Ratio?

The Crescita Therapeutics Inc PE ratio based on its reported earnings over the past 12 months is 9.27. The shares are currently trading at C$0.51.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Crescita Therapeutics Inc?

We were unable to find the directors for Crescita Therapeutics Inc.

Who are the major shareholders of Crescita Therapeutics Inc?

Here are the top five shareholders of Crescita Therapeutics Inc based on the size of their shareholding:

Knight Therapeutics, Inc. Corporation
Percentage owned: 5.15% (1.07m shares)
Chicoine (Daniel N) Individual Investor
Percentage owned: 5.05% (1.05m shares)
London (John C) Individual Investor
Percentage owned: 0.93% (194k shares)
Copeland (David A) Individual Investor
Percentage owned: 0.46% (95.4k shares)
Dobranowski (Anthony E) Individual Investor
Percentage owned: 0.43% (89.9k shares)
Similar to CTX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.